

REVIEW

p16/Ki-67 dual staining as a predictive value for cervical cancer compared to other conventional triage tools: a descriptive literature review

Ana Acosta Bedon^{1,†}, Dayanara Delgado-López^{1,†}, Cristina Ochoa-Avilés², Roque Rivas-Párraga³, Bernardo Vega Crespo¹, Veronique Verhoeven⁴, Vivian Alejandra Neira^{2,5,*}

¹Faculty of Medical Sciences, University of Cuenca, 010203 Cuenca, Ecuador

²Biosciences Department, Faculty of Chemical Sciences, University of Cuenca, 010203 Cuenca, Ecuador

³Faculty of Life Sciences, Ikiam Regional Amazon University, 150101 Tena, Ecuador

⁴Family Medicine and Population Health, University of Antwerp, 2610 Antwerp, Belgium

⁵Faculty of Medicine, University of Azuay, 010203 Cuenca, Ecuador

***Correspondence**

vivian.neira@ucuenca.edu.ec
(Vivian Alejandra Neira)

† These authors contributed equally.

Abstract

Cervical cancer (CC) poses a significant global health concern, ranking as the fourth most frequently diagnosed cancer and the fourth leading cause of death among women worldwide. Ecuador bears a substantial burden of CC, with a considerable number of new cases and deaths reported annually. The primary cause of CC is the human papillomavirus (HPV), a sexually transmitted virus that is usually eliminated by cell immunity. However, around 5% of infections persist and can lead to invasive cancer. This literature review assessed the predictive value of p16 and Ki-67 dual staining (DS) as a standalone method or combined with conventional triage methods to improve CC screening programs. A total of 42 relevant articles were analyzed, evaluating the performance of DS in predicting cervical intraepithelial neoplasia (CIN) of varying severities. DS exhibited a median sensitivity and specificity of 87.7% and 76.7% for detecting CIN2+ and 89.7% and 79.6% for CIN3+. When combined with liquid-based (LB) cytology, DS demonstrated superior sensitivity and specificity compared to other screening strategies. This review suggests that p16 and Ki-67 DS alone or in combination with liquid base (LB) could enhance the accuracy and effectiveness of CC screening.

Keywords

Dual staining; p16; Ki-67; Cytology; Cervical cancer

1. Introduction

Cervical cancer (CC) is the fourth most commonly diagnosed cancer and the fourth leading cause of death in women worldwide, with over 600,000 new cases and more than 300,000 deaths reported in 2020 [1, 2]. In Ecuador, CC ranks as the second most common type of cancer, with an estimated 1500 new cases and over 800 deaths in the same year [3, 4].

Human papillomavirus (HPV) is a sexually transmitted virus that is responsible for causing CC [5]. While most HPV infections typically clear within two years, persistent infections can lead to disease progression [6]. The literature categorizes HPV types based on their oncogenic potential. High-risk HPV types (HR-HPV) associated with precancerous lesions include 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66 and 68 [7]. Conversely, low-risk HPV types (LR-HPV) such as 6, 11, 42, 43 and 44 primarily cause genital warts [8]. Lastly, there are unclassified-risk HPV types, namely 26, 34, 40, 54, 55, 57, 61, 67, 69, 70, 71, 72, 73, 82, 83 and 84 [8, 9].

The screening tools commonly used for CC detection include cytology-based methods, liquid-based (LB) cytology, and HPV DNA testing. The Pap smear, also known as cytology-based screening, involves collecting superficial

epithelial cells from the transformation zone and immediately fixing them on a glass slide. This technique has a sensitivity of approximately 60% and depends on the perspective of the observer [5, 8–10]. In LB cytology, epithelial cells are suspended in a liquid medium and then transferred to a slide for examination. LB cytology exhibits similar sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) to a Pap smear [5, 7, 11]. Another screening tool is HPV DNA testing, which determines the presence of the genetic material of the HPV virus in the sample and also indicates the genotype of the HPV infection in women. It can be done by self-sampling, a urine test, or taken by a physician [11, 12]. According to the literature, HPV testing has been used as a standard test for CC screening, with reported sensitivity and specificity ranging from 65% to 95%, and 50% to 85%, respectively [13–16].

Most screening programs use cytology and/or HPV testing as triage tools. However, these techniques do not provide a persistence or progression prognostic for CIN2+. To improve CC screening programs, different approaches have emerged, such as dual staining (DS) of the CC-related proteins p16 and Ki-67. This technique identifies the co-expression of p16 (a tumor suppressor marker) and Ki-67 (a proliferative

marker) in the same cervical epithelial cell [5, 17]. p16 is a cyclin-dependent kinase inhibitor that facilitates the re-binding of retinoblastoma protein (Rb) and E2F transcription factor. However, its function is disturbed by E7 oncoprotein from HR-HPV when it interrupts the Rb-E2F pathway, leading to an overexpression of p16. It indicates an HR-HPV-induced transformation in cervical epithelial cells [17–19]. The Ki-67 antigen, a nuclear protein expressed throughout the cell cycle except in G0, is typically limited to the basal layer of squamous epithelium in the uterine cervix under normal physiological conditions [17]. Dual expression is necessary to determine the risk of cervical cancer, since their presence is mutually exclusive in a normal cell [20]. Several studies have analyzed the sensitivity and specificity of DS of both proteins compared to or in combination with other screening tools to predict the risk of CC. However, little is known about the correct management of women in CC screening programs when one protein (either p16 or Ki-67) shows positivity in women with positive HR-HPV test or CIN2+ cytology.

To improve CC screening programs, we aimed to review the scientific evidence of p16 and Ki-67 DS as predictive values for CC and precancer alone or when combined with other conventional triage tools. This review also includes what is known about the independent expression of either protein and its relation to CC.

2. Materials and methods

2.1 Data source and search strategy

The PubMed database served as our sole data source. Four keywords were employed to locate articles related to our topic of interest: p16, Ki-67, cervical cancer, and women. In addition, three filters were applied in the search, targeting sex (female), age (adult: 19–44 years, middle-aged: 45–64 years), and a timeline (since 2013). The literature search identified 101 articles up to 15 February 2023. Forty-one articles lacking the specified keywords in their titles were removed from the PubMed list before proceeding to the screening stage.

2.2 Screening

This review included original research articles discussing the proteins of interest and CC. The remaining 60 studies were uploaded to the web tool Rayyan for systematic review by a researcher [21]. A blind first screening was done by two other researchers, who only read abstracts. After reaching a consensus, 11 articles were excluded. Finally, a second blind screening by the same two researchers was conducted to assess methods and materials, excluding seven articles. Studies were excluded for the following reasons: (1) being reviews or non-original articles; (2) being non-English articles; (3) not being related to the keywords; and (4) not being accessible. Fig. 1.




FIGURE 1. Flowchart of the screening process. Most articles were divided into Table 1 (n = 9) and Table 2 (n = 29), based on the classification of each table. However, four articles were included in both, since they met both requirements. The eight articles that were not included in the tables were analyzed in the results section.

2.3 Data collection and extraction

An online Excel document, containing the extraction matrix, was designed and used for this stage [22]. The data collected from the 42 selected articles by the two previous researchers encompassed various parameters, including the title, language, study year, publication year, country/city, study design, age group, median age, type of sample, recruitment method, sample size, final sample size, statistical analysis method, dependent variable, independent variable, objectives, results, conclusions, limitations and future studies, abstract and keywords. Additionally, the impact factor (IF) of the journal at the time each article was published was included as an additional parameter for evaluation.

2.4 Data analysis

Microsoft Excel was used to calculate averages, maximums and minimums. In addition, to determine the strategy that optimally combines high sensitivity and specificity, an analysis was conducted to generate a likelihood ratio plot illustrating the performance characteristics of different triage tests. RStudio (version 2023.03.0) and the ggplot2 package (version 3.4.2) (Posit Software, Boston, MA, USA) were utilized for this purpose [23, 24]. In constructing the likelihood ratio graph, $1 - \text{specificity}$ was plotted on the x-axis, and sensitivity on the y-axis. Additionally, LR^+ and LR^- slopes were computed using the mean values of sensitivity and specificity reported for all diagnostic methods. LR^+ was calculated as $(\text{sensitivity} / (1 - \text{specificity}))$, and LR^- as $(1 - \text{sensitivity}) / \text{specificity}$. For the Youden Index line, a slope of 1 and the calculated Youden Index value were used as the cut-off point. For the LR^+ line, the LR^+ value served as the slope, and the cut-off point was set at (1,1). Lastly, for the LR^- line, the cut-off point was (0,0), and the slope was determined by the LR^- value. This approach facilitated the identification of distinct regions on the graph that determined the most effective overall strategies, the least effective overall strategies, those best suited for detecting the presence, and those best for detecting the absence [25].

3. Results

Detailed information about articles reporting the specificity and sensitivity of p16/Ki-67 DS is presented in two main tables.

Table 1 compares p16/Ki-67 DS alone as a triage strategy to predict CIN2+ and CIN3+ in nine articles. The final sample ranges from 93 to 25,577 women, with an average of 3193 participants. The age range is from 15 to 88 years old; however, some studies also classified their results from women older and younger than 30 years old [26–30]. Most studies used histopathology as a gold standard, and only one used cytology [31]. To identify CIN2+/3+ lesions, the highest sensitivity for p16/Ki-67 DS alone was 90.9% and 93.1% [32], and the lowest was 80.7% and 86.8% [28], with an average of 87.8% and 89.7%, respectively. On the other hand, the highest specificity for predicting CIN2+/3+ lesions were 95.2% and 94.8% [29], and the lowest was 63% [27] and 69.4% [28], with an average of 76.7% and 79.6%, respectively. For women older than 30 years old, the highest sensitivity found was 91% [27] and

91.3% [26], and the lowest was 81.2% and 85.4% [28], for CIN2+/3+ respectively. For specificity, the highest was 96.2% and 95.9% [29], and the lowest was 67% [27] and 75.2% [28], correspondingly. In addition, the average IF of the articles from Table 1 is 5.34.

Table 2 reports the results of 29 articles that used p16/Ki-67 DS in combination with other triage strategies to predict CIN2+ and CIN3+. To assess the sensitivity and specificity of strategies involving various cytology types (including LB), there exist variations among authors in terms of the cytology categories included in the analysis. Table 2 elucidates these differences, with specific notations to convey the inclusions for each cytology category. An asterisk (*) appended to a particular cytology category indicates that the authors considered data solely from that specific cytology category. On the other hand, if a cytology category is denoted with a plus sign (+), it indicates that the analysis encompassed that category and more severe cases. Lastly, in cases where no mark is added, it is implied that all the cytology categories under the Bethesda System were encompassed in the sensitivity and specificity analysis.

Using the likelihood ratio graph, the strategies found to have the highest sensitivity and specificity were those that combined LB cytology plus p16/Ki-67 DS, as shown in Fig. 2A. Strategies placed in the upper left corner correspond to the best fit for sensitivity and specificity, as explained in Fig. 2B. Furthermore, the mean IF from articles listed in Table 2 is 4.20.

Articles analyzing p16/Ki-67 DS alone and in combination are included in both tables. The remaining eight articles were not included in either table, as they lacked data on sensitivity or specificity. However, they were still included in the review because they provide additional information about the performance of p16/Ki-67 DS as a predictor of HSIL and CC. Studies show similar results when comparing p16/Ki-67 DS positivity with increasing cytology or histology severity [60–66], including a study that also links HR-HPV with high expression of p16/Ki-67 [65]. Moreover, one study found a correlation between positive p16/Ki-67 DS results and significantly higher cumulative five-year risks of $\geq \text{CIN2}$ [60]. In contrast, another study concluded that p16/Ki-67 DS did not provide any information about the progression or persistence of HSIL/CIN2± in HR-HPV-positive women. However, the authors also mentioned that the difference among the study populations could be the reason for such discordance with the literature [67]. Finally, only two studies included the analysis of the expression of p16 or Ki-67 individually. One study found differences in the positivity of one of the two proteins in CIN2/3 patients. Three cases of p16-negative CIN2/3 showed Ki-67 positivity, while six cases of Ki-67-negative CIN2/3 exhibited p16 positivity [63]. Another study also found a few cases of CIN2/3 where only one protein was positive. In addition, the authors analyzed the expression of Ki-67 in the lower, medium, and higher third of the epithelium from cervical biopsies in comparison with CC lesion severity. The authors concluded that a combination of p16 negativity and the absence of Ki-67 staining beyond the lower third of the epithelium almost ruled out high-grade lesions [61].

TABLE 1. Sensitivity and specificity of p16/Ki-67 DS alone as a triage strategy to predict CIN2+ and CIN3+.

First Author; Year	Final Sample	Age Group	Gold Standard	Sensitivity % 95% Confidence interval (CI)	Specificity % 95% Confidence interval (CI)
S.K. Zhang <i>et al.</i> [26] 2019	537	20–79	Histopathology	CIN2+ 88.1 (83.0–91.8) CIN3+ 91.3 (85.9–94.7)	CIN2+ 85.0 (80.7–88.4) CIN3+ 76.8 (72.3–80.8)
A. Celewicz <i>et al.</i> [27] 2018	93	16–64	Histopathology	CIN2+ 90	CIN2+ 63
M. El-Zein <i>et al.</i> [28] 2021	492	19–73	Histopathology	CIN2+ 80.7 (75.0–85.6) CIN3+ 86.8 (79.7–92.1)	CIN2+ 69.4 (60.9–77.1) CIN3+ 69.4 (60.9–77.1)
H. Ikenberg <i>et al.</i> [29] 2013	25,577	≥18	Histopathology	CIN2+ 86.7 (81.1–90.9) CIN3+ 87.4 (79.5–92.5)	CIN2+ 95.2 (94.9–95.4) CIN3+ 94.8 (94.5–95.1)
K. Prigenzi <i>et al.</i> [30] 2018	151	15–62	Histology	HSIL 61.5 (31.6–86.1)	HSIL 91.1 (80.4–97.0)
P.J. Toliman <i>et al.</i> [31] 2020	243	30–59	LB Cytology	HSIL+ Cervical Specimens 100.0 (84.6–100.0) Vaginal Specimens 68.2 (45.1–86.1)	HSIL+ Cervical Specimens 79.6 (70.0–87.2) Vaginal Specimens 84.9 (76.0–91.5)
L. Yu <i>et al.</i> [32] 2016	1290	30–69	Histopathology	CIN2+ 90.9 (86.5–94.0) CIN3+ 93.1 (88.6–96.0)	CIN2+ 79.5 (77.0–81.8) CIN3+ 77.2 (74.6–79.6)
R. Zhang <i>et al.</i> [33] 2018	223	20–73	Histopathology	CIN2+ 90.2 (84.5–94.3)	CIN2+ 68.3 (55.0–79.7)
S. Amaro-Filho <i>et al.</i> [34] 2013	130	24–88	Histopathology	FIGO III+ 66.7 FIGO II+ 53.3	FIGO III+ 70.0 FIGO II+ 81.8

Notes: CIN2+: Cervical Intraepithelial Neoplasia Grade 2+; CIN3+: Cervical Intraepithelial Neoplasia Grade 3+; HSIL: High-grade squamous intraepithelial lesion; FIGO III+: International Federation of Gynecology and Obstetrics System Grade 3; FIGO II+: International Federation of Gynecology and Obstetrics System Grade 2; LB: Liquid-based; DS: Dual staining.

TABLE 2. Sensitivity and specificity of p16/Ki-67 DS in combination with other triage strategies to predict CIN2+ and CIN3+.

First Author; Year	Final Sample	Histology	LB cytology + p16/Ki-67 DS	HR-HPV + p16/Ki-67 DS	HR-HPV (other) + p16/Ki-67 DS	HPV16/18 + p16/Ki-67 DS	HR-HPV + LB cytology + p16/Ki-67 DS
					Sensitivity % (95% CI) Specificity % (95% CI)		
A. Celewicz <i>et al.</i> [27] 2018	93	CIN2+	86 74				
			ASC-US+				
		CIN2+	96.1 (92.6–98.2)	85.0 (77.7–90.6)			
			40.3 (31.9–49.1)	48.4 (30.2–66.9)			
M. El-Zein <i>et al.</i> [28] 2021	492	CIN3+	96.9 (92.3–99.2)	86.4 (77.0–93.0)			
			40.3 (31.9–49.1)	48.4 (30.2–66.9)			
			LSIL+				
		CIN2+	91.7 (87.3–94.9)				
			53.0 (44.2–61.7)				
		CIN3+	96.1 (91.2–98.7)				
			53.0 (44.2–61.7)				
			ASC-US and LSIL				
L. Yu <i>et al.</i> [32] 2016	1290	CIN2+	87.5 (75.3–94.1)	92.7 (88.4–95.4)			
			66.4 (59.7–72.4)	52.7 (46.4–58.8)			
		CIN3+	89.7 (73.6–96.4)	95.0 (90.7–97.3)			
			62.1 (55.7–68.2)	47.7 (42.0–53.5)			
			ASC-US				
			89.0 (81.7–96.4)				
R. Zhang <i>et al.</i> [33] 2018	223	CIN2+	71.4 (60.7–82.0)	90.8 (85.1–94.9)			
			LSIL	70.2 (55.1–82.7)			
			89.1 (80.5–97.8)				
			61.5 (48.0–75.0)				
				75.2 (68.1–81.6)		90.1 (76.9–96.5)	
P. Giorgi Rossi <i>et al.</i> [35] 2021	3147	CIN2+		74.8 (72.4–77.1)		53.7 (49.9–57.5)	
		CIN3+		80.6 (70.9–88.3)		100.0 (85.8–100.0)	
			ASC-US				
			90.4 (68.0–98.0)				
M. Magkana <i>et al.</i> [36] 2021	196	CIN2+	97.2 (89.0–99.0)				
			LSIL				
			95.0 (85.0–99.0)				
			95.2 (83.0–99.0)				

TABLE 2. Continued.

First Author; Year	Final Sample	Histology	LB cytology + p16/Ki-67 DS	HR-HPV + p16/Ki-67 DS	HR-HPV (other) + p16/Ki-67 DS	HPV16/18 + p16/Ki-67 DS	HR-HPV + LB cytology + p16/Ki-67 DS
					Sensitivity % (95% CI) Specificity % (95% CI) (12) [†]		
Y. Hu <i>et al.</i> [37] 2020	846	CIN2+		63.4 (54.4–71.9) 85.2 (82.5–87.8)	86.5 (79.3–91.9) 62.5 (58.8–66.0)		
		CIN3+		64.6 (55.2–73.3) 84.7 (82.0–87.3)	87.0 (79.6–92.6) 61.9 (58.3–65.5)		
		CIN2+		89.0 (86.3–91.4) 49.1 (42.1–56.0)	(12) [†] 97.1 (95.5–98.3) 41.5 (34.8–48.5)		
		CIN3+		89.8 (87.1–92.2) 44.8 (38.6–51.2)	98.3 (96.9–99.2) 38.1 (32.1–44.4)		
M.Y. Jiang <i>et al.</i> [38] 2020	1757	CIN2+			(8) [‡] 96.1 (94.3–97.5) 48.6 (41.7–55.5)		
		CIN3+			97.4 (95.8–98.5) 44.4 (38.2–50.8)		
		CIN2+		85.5 (80.2–90.9) 60.0 (54.3–65.7)			
		CIN3+		93.8 (88.6–99.1) 51.2 (46.1–56.4)			
R. Luttmer <i>et al.</i> [39] 2016	446	CIN2+		83.4 (77.1–88.6) 58.9 (56.2–61.6)			
		CIN3+		86.9 (78.6–92.8) 56.9 (54.2–59.5)			
		CIN2+					
		CIN3+					
N. Wentzensen <i>et al.</i> [40] 2015	1509	CIN3+					
		CIN2/3		88.0 (79.0–94.0) 31.0 (23.0–40.0)			ASC-US 71.0 (60.0–80.0) 49.0 (40.0–59.0)
I.T. Ovestad <i>et al.</i> [41] 2017	266	CIN3		94.0 (82.0–98.0) 28.0 (22.0–36.0)			86.0 (73.0–94.0) 50.0 (41.0–58.0)

TABLE 2. Continued.

First Author; Year	Final Sample	Histology	LB cytology + p16/Ki-67 DS	HR-HPV + p16/Ki-67 DS	HR-HPV (other) + p16/Ki-67 DS	HPV16/18 + p16/Ki-67 DS	HR-HPV + LB cytology + p16/Ki-67 DS
					Sensitivity % (95% CI) Specificity % (95% CI)		
D. Gustinucci <i>et al.</i> [42] 2016	6272	CIN2+		87.6 (75.7–93.6) 74.9 (69.0–79.0)			ASC-US+ 93.8 (85.0–98.3) 59.2 (53.4–64.6)
		CIN3+		92.3 (74.9–99.1)			100.0 (89.1–100.0)
		CIN2+					HSIL 89.2 (79.1–95.6) 74.2 (68.4–78.5)
		CIN3+					96.2 (80.4–99.9)
		CIN2+		86.0 (79.0–92.0) 73.0 (65.0–81.0)			ASC-US and LSIL 89.0 (82.0–94.0) 79.0 (70.0–85.0)
R.M. Ebisch <i>et al.</i> [43] 2017	462	CIN3+		92.0 (84.0–97.0) 61.0 (54.0–69.0)			92.0 (84.0–97.0) 64.0 (56.0–71.0)
		CIN2+					NILM 97.0 (92.0–99.0) 55.0 (46.0–63.0)
		CIN3+					97.0 (91.0–100.0) 43.0 (35.0–51.0)
		CIN2+					
		CIN3+					NILM, ASC-US and LSIL 92.0 (85.0–96.0) 71.0 (62.0–78.0)
P. Ziemke <i>et al.</i> [44] 2014	260	CIN2+	74.5 (67.8–80.3) 90.0 (78.8–95.9)				96.0 (89.0–99.0) 58.0 (50.0–65.0)
L. Pirtea <i>et al.</i> [45] 2018	310	CIN2/3	ASC-US 66.0				
			93.0				
			LSIL 59.0				
			79.0				

TABLE 2. Continued.

First Author; Year	Final Sample	Histology	LB cytology + p16/Ki-67 DS	HR-HPV + p16/Ki-67 DS	HR-HPV (other) + p16/Ki-67 DS	HPV16/18 + p16/Ki-67 DS	HR-HPV + LB cytology + p16/Ki-67 DS
					Sensitivity % (95% CI) Specificity % (95% CI)		
			ASC-US				
		CIN2+	87.5 (47.3–99.7) 81.1 (75.8–85.7)				
C. Bergeron <i>et al.</i> [46] 2015	25,577	CIN3+	100.0 (54.1–100.0) 80.8 (75.5–85.4)				
			LSIL				
		CIN2+	86.5 (71.2–95.5) 56.0 (48.3–63.5)				
		CIN3+	88.2 (63.6–98.5) 51.8 (44.5–59.0)				
T. Wright <i>et al.</i> [47] 2022	5250	CIN2+		86.5 (83.3–89.1) 57.5 (55.8–59.1)		90.2 (87.4–92.5) 40.9 (39.3–42.6)	
		CIN3+		89.5 (84.9–92.9) 54.0 (52.4–55.6)		94.3 (90.5–96.7) 38.6 (37.0–40.2)	
			ASC-US+				
		CIN2+	75.4 (72.3–78.8) 88.3 (87.2–89.4)				
		CIN3+	79.2 (74.5–83.8) 75.2 (73.4–77.0)				
C. White <i>et al.</i> [48] 2016	471		LSIL				
		CIN2+	77.8 (74.0–81.5) 88.6 (87.1–90.1)				
		CIN3+	85.7 (81.7–89.8) 72.7 (70.2–75.2)				
			ASC-US				
		CIN2+	71.9 (66.7–77.2) 87.9 (86.2–89.6)				
		CIN3+	71.4 (60.7–82.1) 78.7 (76.2–81.2)				

TABLE 2. Continued.

First Author; Year	Final Sample	Histology	LB cytology + p16/Ki-67 DS	HR-HPV + p16/Ki-67 DS	HR-HPV (other) + p16/Ki-67 DS	HPV16/18 + p16/Ki-67 DS	HR-HPV + LB cytology + p16/Ki-67 DS
					Sensitivity % (95% CI) Specificity % (95% CI)		
M. Uijterwaal <i>et al.</i> [49] 2015	762	CIN2+					68.8 (53.7–81.3)
		CIN3+					72.8 (67.9–77.3)
							73.3 (44.9–92.2)
							70.0 (65.2–74.6)
Q.P. Qian <i>et al.</i> [50] 2018	108	HSIL+	96.0 (82.0–100.0) 60.0 (48.0–71.0)		(21) [§] 96.0 (82.0–100.0) 35.0 (25.0–46.0)		
M. Stoler <i>et al.</i> [51] 2019	8067	CIN3+		85.9 60.1			
Y.J. Koo <i>et al.</i> [52] 2013	70	CIN2+	ASC-H 94.6 (84.1–99.0) 75.8 (64.0–80.7)				
		CIN3+	100.0 (79.7–100.0) 50.9 (44.4–50.9)				
C. Solares <i>et al.</i> [53] 2015	160	CIN2+					82.4 (61.28–100.0) 78.3 (71.2–85.4)
G. Trutnovsky <i>et al.</i> [54] 2014	27	CIN2+	ASC-US+ 100 66.7				
J. Ordi <i>et al.</i> [55] 2014	1123	HSIL/CC					ASC-US 90.9 (87.9–93.9) 72.1 (68.7–75.4)

TABLE 2. Continued.

First Author; Year	Final Sample	Histology	LB cytology + p16/Ki-67 DS	HR-HPV + p16/Ki-67 DS	HR-HPV (other) + p16/Ki-67 DS	HPV16/18 + p16/Ki-67 DS	HR-HPV + LB cytology + p16/Ki-67 DS
					Sensitivity % (95% CI) Specificity % (95% CI)		
T. Fujii <i>et al.</i> [56] 2014	479	CIN2+	ASC-US and LSIL 87.3 (78.0–93.8) 76.4 (71.6–80.8)				
J. Killeen <i>et al.</i> [57] 2013	515	CIN2/3	ASC-US+ 94.2 61.9				
							NILM 100.0 (50.0–100.0) 71.4 (41.9–91.6)
C. Areán-Cuns <i>et al.</i> [58] 2018	3810	CIN2+		98.0 (93.1–99.8) 39.1 (32.3–46.2)			ASC-US 91.6 (61.5–99.8) 51.6 (33.1–69.8) LSIL 97.9 (88.9–100.0) 34.4 (26.8–42.7)
N. Lorenzi <i>et al.</i> [59] 2022	232	CIN2+	HP 84.4 (74.3–91.6) 59.2 (38.8–77.6) SP 70.6 (59.0–80.6) 85.7 (67.3–95.9)				

Notes: + Includes the cases of that cytology category and more severe. 12[†] HR-HPV genotypes, except for 16/18. 8[‡] HR-HPV genotypes (HPV31/33/58/52/45/59/56/66). 21[§] HPV genotypes (HR: 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66 and 68; LR: 6, 11, 42, 43, 44 and CP8304(81)). CIN2+: Cervical Intraepithelial Neoplasia Grade 2+; CIN3+: Cervical Intraepithelial Neoplasia Grade 3+; NILM: Negative for intraepithelial lesions or malignancy; ASC-H: Atypical squamous cells; ASC-US: Atypical squamous cells of undetermined significance; LSIL: Low-grade squamous intraepithelial lesion; HSIL: High-grade squamous intraepithelial lesion; HSIL/CC: High-grade intraepithelial lesion or carcinoma; LB: Liquid-based; HP: Health professional; SP: Self-sampling; DS: Dual staining; HR-HPV: High-risk human papillomavirus; CI: Confidence interval.




FIGURE 2. Sensitivity and specificity of different standalone or combined screening strategies plus p16/Ki-67 DS. (A) Likelihood ratio graph of the combined strategies from Table 2, by region. (B) Regions of comparison of the likelihood ratio graph. CIN2/3: Cervical Intraepithelial Neoplasia grades 2 and 3; CIN2+: Cervical Intraepithelial Neoplasia grade 2 or higher; CIN3+: Cervical Intraepithelial Neoplasia grade 3 or higher; HSIL/CC: High-Grade Squamous Intraepithelial Lesion/Cervical Cancer; HSIL+: High-Grade Squamous Intraepithelial Lesion; ASC-US: Atypical Squamous Cells of Undetermined Significance; DS: Dual Staining; HPV: Human Papillomavirus; HR-HPV: High-Risk HPV; LSIL: Low-Grade Squamous Intraepithelial Lesion; NILM: Negative for Intraepithelial Lesion; LB: Liquid-base cytology; ASC-H: Atypical Squamous Cells.

4. Discussion

Analyzing the latest available data on the predictive capabilities of p16/Ki-67 DS in the identification and prevention of CC, this review explores its applicability in screening programs and draws comparisons with established techniques. According to the literature, cytology and HPV testing, when used independently, have shown low sensitivity and specificity for the diagnosis of CIN2+ [68, 69].

Currently, various triage strategies are being evaluated, including p16/Ki-67 DS. In the Bethesda System for Reporting Cervical Cytology 2014 edition, DS was recommended as a complementary test for cytological diagnosis [70]. This review found that the median sensitivity and specificity of p16/Ki-67 DS for diagnosing CIN2+ were 87.7% and 76.7%, respectively. For CIN3+, the median sensitivity was 89.7% and specificity 79.6%. These findings are consistent with other studies that have demonstrated that DS exhibits higher sensitivity and specificity in detecting CIN3+ compared to CIN2+ [13, 17, 71]. Another study performed in China revealed that DS sensitivity and specificity were not higher than cytology in HPV-positive women [32]. Therefore, although DS reduces the repeat cytology and colposcopy referral rate, there is a need to enhance its sensitivity and specificity. There is increasing evidence that p16/Ki-67 DS is an alternative biomarker to improve screening programs. Some reviews also concluded that p16/Ki-67 DS increases the sensitivity of detecting precancerous lesions and is a marker for transforming HPV infections [14, 72, 73]. Some authors have also evaluated the interobserver reproducibility and accuracy of the technique. They mostly found satisfactory results above 80%, suggesting its implementation in screening programs [74, 75].

Our review found higher sensitivities and specificities for the combined strategy of DS plus LB cytology. These findings are consistent with those from other reviews or original research where the sensitivities and specificities were higher compared to other triage strategies such as HR-HPV [13, 76]. While HPV testing is expected to replace cytology as a triage tool worldwide due to its high sensitivity, it may also lead to overtreatment, since many HPV infections in young women are transient and likely to resolve within the next two years [77–79]. Considering the evidence previously presented and based on our results, DS plus LB cytology demonstrates effective predictive accuracy specifically for high-grade lesions [77, 80].

This review also found a positive relationship between p16/Ki-67 expression and CC lesion severity. Other studies further confirmed that a higher number of positive cells relate to worse histopathology results [20, 81, 82]. These results contribute to the understanding of p16/Ki-67 DS as an important predictor of HSIL/CC. On the other hand, the present review did not find extensive information when only one protein is expressed in a patient with cervical lesions. Studies that analyzed the expression of the proteins independently usually found very few cases where only one protein was expressed in this context. However, the overexpression of either p16 or Ki-67 still correlated with the degree of neoplasia [61]. A possible explanation could be that if left untreated, approximately 30% of CIN3 lesions and approximately 10% of CIN2 lesions will develop into invasive cancer [83, 84]. Thus, the regression of CIN2 and CIN3 lesions might change the overexpression of the proteins. Another study suggested that since Ki-67 had significantly higher positive cells for CIN3+ than CIN2+, p16

overexpression might be an early event, and Ki-67 expression increases throughout CIN progression [63]. However, a consensus on this matter has not been reached based on the available information.

Some limitations of this review are that only English articles and one database were used for the analysis.

5. Conclusions

In summary, this review presented sensitivity and specificity estimates of DS alone and in combination with other techniques for CC screening. When detecting precancerous lesions, DS alone exhibited higher sensitivity and specificity for CIN3+ compared to CIN2+. Among the combined strategies, DS along with LB cytology demonstrated higher sensitivities and specificities compared to other reviewed strategies. However, evidence suggests that HPV testing may be more suitable for triage screening. When analyzing the immunohistochemistry staining of p16 and Ki-67 independently, together, or in combination with other strategies, it has high predictive value for CC and its precursors. This review found that using p16/Ki-67 DS alone or in combination with LB cytology could improve the accuracy and efficacy of CC screening and therefore, the potential to enhance CC screening programs. Future literature and systematic reviews are needed to accurately analyze the effects, performance, and cost-effectiveness of DS and cytology/HPV co-testing.

ABBREVIATIONS

LB, Liquid-based; DS, Dual staining; NILM, Negative for intraepithelial lesions or malignancy; ASC-US, Atypical squamous cells of undetermined significance; ASC-H, Atypical squamous cells; LSIL, Low-grade squamous intraepithelial lesion; HSIL, High-grade squamous intraepithelial lesion; HSIL/CC, High-grade intraepithelial lesion or carcinoma; CIN2+, Cervical Intraepithelial Neoplasia Grade 2+; CIN3+, Cervical Intraepithelial Neoplasia Grade 3+; FIGO II+, International Federation of Gynecology and Obstetrics System Grade 2; FIGO III+, International Federation of Gynecology and Obstetrics System Grade 3; HP, Health professional; SP, Self-sampling.

AVAILABILITY OF DATA AND MATERIALS

The data presented in this study are openly available at <https://rpubs.com/rgrivas71/1075694>.

AUTHOR CONTRIBUTIONS

AAB, DDL, COA and VAN—conducted the research study. AAB, DDL and RRP—implemented the methodology, curated the data, handled the visualization. BVC—performed the validation of the study. AAB and DDL—conducted the investigation, prepared the original draft of the article. AAB, DDL and VV—contributed to the writing, review and editing. COA and VAN—supervised the investigation, managed project administration. VAN and VV—acquired funding. All

authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Not applicable.

ACKNOWLEDGMENT

We acknowledge the Department of Bioscience of the University of Cuenca for the support and contribution with advice and experience to this article through the writing group number 4.

FUNDING

This research was funded by COENCA, grant number: EC2022TEA511A102.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

- [1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, *et al.* Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*. 2021; 71: 209–249.
- [2] World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. World Health Organization: Geneva, Switzerland. 2020.
- [3] Vega Crespo B, Neira VA, Ortiz Segarra J, Andrade A, Guerra G, Ortiz S, *et al.* Barriers and facilitators to cervical cancer screening among under-screened women in Cuenca, Ecuador: the perspectives of women and health professionals. *BMC Public Health*. 2022; 22: 2144.
- [4] Ortiz Segarra J, Vega Crespo B, Campoverde Cisneros A, Salazar Torres K, Delgado López D, Ortiz S. Human papillomavirus prevalence and associated factors in indigenous women in Ecuador: a cross-sectional analytical study. *Infectious Disease Reports*. 2023; 15: 267–278.
- [5] Voidāzan ST, Dianzani C, Husariu MA, Geréd B, Turdean SG, Uzun CC, *et al.* The role of p16/Ki-67 immunostaining, hTERC amplification and fibronectin in predicting cervical cancer progression: a systematic review. *Biology*. 2022; 11: 956.
- [6] Public Health Ministry. National strategy for comprehensive cancer care in Ecuador. 2017. Available at: https://aplicaciones.msp.gob.ec/salud/archivosdigitales/documentosDirecciones/dnn/archivos/ac_0059_2017.pdf (Accessed: 15 November 2023).
- [7] Bakir A, Alacam S, Karabulut N, Beka H, Ozluk Y, Yilmazbayhan D, *et al.* Evaluation of human papillomavirus genotype distribution in cervical samples. *Journal of Cytology*. 2021; 38: 44–49.
- [8] Luria L; Cardoza-Favarato G. Human papillomavirus. StatPearls Publishing: St. Petersburg. 2023.
- [9] Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, *et al.* Sexually transmitted infections treatment guidelines, 2021. *MMWR Recommendations and Reports*. 2021; 70: 1–187.
- [10] Patel N, Bavikar R, Buch A, Kulkarni M, Dharwadkar A, Viswanathan V. A comparison of conventional pap smear and liquid-based cytology for cervical cancer screening. *Gynecology and Minimally Invasive Therapy*. 2023; 12: 77–82.
- [11] Bebyn MG, Śledzińska P, Wojtyśiak J, Jóźwicki W, Mierzwa T, Dziedzic J, *et al.* HPV RNA and DNA testing in Polish women screened for cervical cancer—a single oncological center study. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2022; 268: 129–134.

- [12] Vega Crespo B, Neira VA, Ortiz Segarra J, Rengel RM, López D, Orellana MP, *et al.* Role of self-sampling for cervical cancer screening: diagnostic test properties of three tests for the diagnosis of HPV in rural communities of Cuenca, Ecuador. *International Journal of Environmental Research and Public Health*. 2022; 19: 4619.
- [13] Costa S, Verberckmoes B, Castle PE, Arbyn M. Offering HPV self-sampling kits: an updated meta-analysis of the effectiveness of strategies to increase participation in cervical cancer screening. *British Journal of Cancer*. 2023; 128: 805–813.
- [14] Rajaram S, Gupta B. Screening for cervical cancer: choices & dilemmas. *Indian Journal of Medical Research*. 2021; 154: 210–220.
- [15] Arbyn M, Simon M, de Sanjosé S, Clarke MA, Poljak M, Rezhake R, *et al.* Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis. *The Lancet Oncology*. 2022; 23: 950–960.
- [16] Khaja A, Ahr A, Zeiser I, Ikenberg H. Two years of cytology and HPV co-testing in Germany: initial experience. *Geburtshilfe Und Frauenheilkunde*. 2022; 82: 1378–1386.
- [17] Dovnik A, Repše Fokter A. The role of p16/Ki67 dual staining in cervical cancer screening. *Current Issues in Molecular Biology*. 2023; 45: 8476–8491.
- [18] Nieh S, Chen S, Chu T, Lai H, Lin Y, Fu E, *et al.* Is p16INK4a expression more useful than human papillomavirus test to determine the outcome of atypical squamous cells of undetermined significance-categorized Pap smear? A comparative analysis using abnormal cervical smears with follow-up biopsies. *Gynecologic Oncology*. 2005; 97: 35–40.
- [19] Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, *et al.* Overexpression of p16INK4a as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. *International Journal of Cancer*. 2001; 92: 276–284.
- [20] Trzeciech M, Mazurek M, Jach R, Mazurek K, Kotkowska-Szeps I, Kania M, *et al.* p16/Ki67 dual stain triage versus cytology in primary human papillomavirus-based cervical cancer screening with limited genotyping. *Journal of Medical Virology*. 2023; 95: e29271.
- [21] Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. *Systematic Reviews*. 2016; 5: 210.
- [22] Microsoft Excel. Available at: <https://www.microsoft.com/es/microsoft-365/excel?legRedir=true&CorrelationId=a93a8a1d-8610-431d-bc41-ee4de48e56ec&rtc=1?legRedir=true&CorrelationId=a93a8a1d-8610-431d-bc41-ee4de48e56ec&rtc=1> (Accessed: 14 June 2023).
- [23] Posit. 2024. Available at: <https://posit.co/> (Accessed: 13 July 2023).
- [24] Wickham H. *ggplot2: elegant graphics for data analysis*. 2nd edn. Springer International Publishing: Switzerland. 2016.
- [25] Magri V, Wagenlehner FME, Montanari E, Perletti G. Semen analysis in chronic bacterial prostatitis: diagnostic and therapeutic implications. 2009. Available at: https://www.researchgate.net/figure/Likelihood-ratio-LR-graph-regions-of-comparison-27-The-slopes-tangents-of-the_fig1_24308427 (Accessed: 17 August 2023).
- [26] Zhang S, Jia M, Zhao D, Wu Z, Guo Z, Liu Y, *et al.* Evaluation of p16/Ki-67 dual staining in the detection of cervical precancer and cancer in China. *Cancer Epidemiology*. 2019; 59: 123–128.
- [27] Celewicz A, Celewicz M, Węzowska M, Chudecka-Głaz A, Menkiszak J, Urańska E. Clinical efficacy of p16/Ki-67 dual-stained cervical cytology in secondary prevention of cervical cancer. *Polish Journal of Pathology*. 2018; 69: 42–47.
- [28] El-Zein M, Gottlieb W, Gilbert L, Hemmings R, Behr MA, Franco EL. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: results from the screening triage ascertaining intraepithelial neoplasia by immunostain testing study. *International Journal of Cancer*. 2021; 148: 492–501.
- [29] Ikenberg H, Bergeron C, Schmidt D, Griesser H, Alameda F, Angeloni C, *et al.* Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. *JNCI: Journal of the National Cancer Institute*. 2013; 105: 1550–1557.
- [30] Prigenzi K, Heinke T, Salim R, Focchi G. Dual p16 and Ki-67 expression in liquid-based cervical cytological samples compared to pap cytology findings, biopsies, and HPV testing in cervical cancer screening: a diagnostic accuracy study. *Acta Cytologica*. 2018; 62: 104–114.
- [31] Toliman PJ, Phillips S, de Jong S, O'Neill T, Tan G, Brotherton JML, *et al.* Evaluation of p16/Ki-67 dual-stain cytology performed on self-collected vaginal and clinician-collected cervical specimens for the detection of cervical pre-cancer. *Clinical Microbiology and Infection*. 2020; 26: 748–752.
- [32] Yu L, Chen W, Lei X, Qin Y, Wu Z, Pan Q, *et al.* Evaluation of p16/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China. *Oncotarget*. 2016; 7: 21181–21189.
- [33] Zhang R, Ge X, You K, Guo Y, Guo H, Wang Y, *et al.* p16/Ki67 dual staining improves the detection specificity of high-grade cervical lesions. *Journal of Obstetrics and Gynaecology Research*. 2018; 44: 2077–2084.
- [34] Amaro-Filho SM, Golub JE, Nuovo GJ, Cunha CB, Levi JE, Villa LL, *et al.* A comparative analysis of clinical and molecular factors with the stage of cervical cancer in a Brazilian cohort. *PLOS ONE*. 2013; 8: e57810.
- [35] Giorgi Rossi P, Carozzi F, Ronco G, Allia E, Bisanzi S, Gillio-Tos A, *et al.* p16/ki67 and E6/E7 mRNA accuracy and prognostic value in triaging HPV DNA-positive women. *JNCI: Journal of the National Cancer Institute*. 2021; 113: 292–300.
- [36] Magkana M, Mentzelopoulou P, Magkana E, Pampanos A, Daskalakis G, Domali E, *et al.* The p16/ki-67 assay is a safe, effective and rapid approach to triage women with mild cervical lesions. *PLOS ONE*. 2021; 16: e0253045.
- [37] Hu Y, Hong Z, Gu L, Xie L, Yang B, Dai H, *et al.* Evaluation of p16/Ki-67 dual-stained cytology in triaging HPV-positive women during cervical cancer screening. *Cancer Epidemiology, Biomarkers & Prevention*. 2020; 29: 1246–1252.
- [38] Jiang M, Wu Z, Li T, Yu L, Zhang S, Zhang X, *et al.* Performance of HPV genotyping combined with p16/Ki-67 in detection of cervical precancer and cancer among HPV-positive Chinese women. *Cancer Prevention Research*. 2020; 13: 163–172.
- [39] Luttmer R, Dijkstra MG, Snijders PJF, Berkhof J, van Kemenade FJ, Rozendaal L, *et al.* p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population. *Modern Pathology*. 2016; 29: 870–878.
- [40] Wentzensen N, Fetterman B, Castle PE, Schiffman M, Wood SN, Stiemerling E, *et al.* p16/Ki-67 dual stain cytology for detection of cervical precancer in HPV-positive women. *Journal of the National Cancer Institute*. 2015; 107: djv257.
- [41] Ovestad IT, Dalen I, Hansen E, Loge JLD, Dybdahl BM, Dirdal MB, *et al.* Clinical value of fully automated p16/Ki-67 dual staining in the triage of HPV-positive women in the Norwegian cervical cancer screening program. *Cancer Cytopathology*. 2017; 125: 283–291.
- [42] Gustinucci D, Giorgi Rossi P, Cesarini E, Broccolini M, Bulletti S, Carlini A, *et al.* Use of cytology, E6/E7 mRNA, and p16INK4a-Ki-67 to define the management of human papillomavirus (HPV)-positive women in cervical cancer screening. *American Journal of Clinical Pathology*. 2016; 145: 35–45.
- [43] Ebisch RM, van der Horst J, Hermesen M, Rijsternberg LL, Vedder JE, Bulten J, *et al.* Evaluation of p16/Ki-67 dual-stained cytology as triage test for high-risk human papillomavirus-positive women. *Modern Pathology*. 2017; 30: 1021–1031.
- [44] Ziemke P, Marquardt K, Griesser H. Predictive value of the combined p16 and Ki-67 immunocytochemistry in low-grade squamous intraepithelial lesions. *Acta Cytologica*. 2014; 58: 489–494.
- [45] Pirtea L, Secosan C, Margan M, Moleriu L, Balint O, Grigoras D, *et al.* p16/Ki-67 dual staining has a better accuracy than human papillomavirus (HPV) testing in women with abnormal cytology under 30 years old. *Bosnian Journal of Basic Medical Sciences*. 2019; 19: 336–341.
- [46] Bergeron C, Ikenberg H, Sideri M, Denton K, Bogers J, Schmidt D, *et al.* Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results. *Cancer Cytopathology*. 2015; 123: 373–381.
- [47] Wright TC Jr, Stoler MH, Ranger-Moore J, Fang Q, Volkir P, Safaeian M, *et al.* Clinical validation of p16/Ki-67 dual-stained cytology triage of HPV-positive women: results from the IMPACT trial. *International Journal of Cancer*. 2022; 150: 461–471.

- [48] White C, Bakhiet S, Bates M, Keegan H, Pilkington L, Ruttle C, *et al.* Triage of LSIL/ASC-us with p16/Ki-67 dual staining and human papillomavirus testing: a 2-year prospective study. *Cytopathology*. 2016; 27: 269–276.
- [49] Uijterwaal MH, Polman NJ, Witte BI, van Kemenade FJ, Rijkaart D, Berkhof J, *et al.* Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data. *International Journal of Cancer*. 2015; 136: 2361–2368.
- [50] Qian Q, Zhang X, Ding B, Jiang S, Li Z, Ren M, *et al.* Performance of p16/Ki67 dual staining in triaging Hr-HPV-positive population during cervical Cancer screening in the younger women. *Clinica Chimica Acta*. 2018; 483: 281–285.
- [51] Stoler MH, Baker E, Boyle S, Aslam S, Ridder R, Huh WK, *et al.* Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki-67 dual-stained cytology—retrospective insights from ATHENA. *International Journal of Cancer*. 2020; 146: 2599–2607.
- [52] Koo Y, Hahn H, Lee I, Lim K, Lee K, Kim H, *et al.* Dual immunostaining of cervical cytology specimens with atypical squamous cells for p16/Ki-67 does not exclude the existence of a high-grade squamous intraepithelial lesion. *Virchows Archiv*. 2013; 463: 689–696.
- [53] Solares C, Velasco J, Álvarez-Ruiz E, González-Fernández L, Encinas AI, Astudillo A, *et al.* Expression of p16/Ki-67 in ASC-US/LSIL or normal cytology with presence of oncogenic HPV DNA. *Anticancer Research*. 2015; 35: 6291–6295.
- [54] Trutnovsky G, Kolovetsiou-Kreiner V, Reich O. p16/Ki-67 dual-stained cytology testing may predict postpartum outcome in patients with abnormal papanicolaou cytology during pregnancy. *Acta Cytologica*. 2014; 58: 293–296.
- [55] Ordi J, Sagasta A, Munmany M, Rodríguez-Carunchio L, Torné A, del Pino M. Usefulness of p16/Ki67 immunostaining in the triage of women referred to colposcopy. *Cancer Cytopathology*. 2014; 122: 227–235.
- [56] Fujii T, Saito M, Hasegawa T, Iwata T, Kuramoto H, Kubushiro K, *et al.* Performance of p16INK4a/Ki-67 immunocytochemistry for identifying CIN2+ in atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion specimens: a Japanese gynecologic oncology group study. *International Journal of Clinical Oncology*. 2015; 20: 134–142.
- [57] Killeen JL, Dye T, Grace C, Hiraoka M. Improved abnormal pap smear triage using cervical cancer biomarkers. *Journal of Lower Genital Tract Disease*. 2014; 18: 1–7.
- [58] Areán-Cuns C, Mercado-Gutiérrez M, Paniello-Alastruey I, Mallor-Giménez F, Córdoba-Iturriagagoitia A, Lozano-Escario M, *et al.* Dual staining for p16/Ki67 is a more specific test than cytology for triage of HPV-positive women. *Virchows Archiv*. 2018; 473: 599–606.
- [59] Lorenzi NPC, Termini L, Ferreira-Filho ES, Nunes RAL, Silva GAF, Lepique AP, *et al.* A positive HPV test with positive p16/Ki-67 double staining in self-sampled vaginal material is an accurate tool to detect women at risk for cervical cancer. *Cancer Cytopathology*. 2022; 130: 41–54.
- [60] Clarke MA, Cheung LC, Castle PE, Schiffman M, Tokugawa D, Poitras N, *et al.* Five-year risk of cervical precancer following p16/Ki-67 dual-stain triage of HPV-positive women. *JAMA Oncology*. 2019; 5: 181–186.
- [61] Mandal R, Ghosh I, Banerjee D, Mittal S, Muwonge R, Roy C, *et al.* Correlation between p16/Ki-67 expression and the grade of cervical intraepithelial neoplasias. *International Journal of Gynecological Pathology*. 2020; 39: 384–390.
- [62] Miyamoto S, Hasegawa J, Morioka M, Hirota Y, Kushima M, Sekizawa A. The association between p16 and Ki-67 immunohistostaining and the progression of cervical intraepithelial neoplasia grade 2. *International Journal of Gynecology & Obstetrics*. 2016; 134: 45–48.
- [63] Zhong P, Li J, Gu Y, Liu Y, Wang A, Sun Y, *et al.* p16 and Ki-67 expression improves the diagnostic accuracy of cervical lesions but not predict persistent high risk human papillomavirus infection with CIN1. *International Journal of Clinical and Experimental Pathology*. 2015; 8: 2979–2986.
- [64] Yu L, Guo H, Lei X, Qin Y, Wu Z, Kang L, *et al.* p16/Ki-67 co-expression associates high risk human papillomavirus persistence and cervical histopathology: a 3-year cohort study in China. *Oncotarget*. 2016; 7: 64810–64819.
- [65] Calil LN, Edelweiss MIA, Meurer L, Igansi CN, Bozzetti MC. P16INK4a and Ki67 expression in normal, dysplastic and neoplastic uterine cervical epithelium and human papillomavirus (HPV) infection. *Pathology—Research and Practice*. 2014; 210: 482–487.
- [66] Shi Q, Xu L, Yang R, Meng Y, Qiu L. Ki-67 and p16 proteins in cervical cancer and precancerous lesions of young women and the diagnostic value for cervical cancer and precancerous lesions. *Oncology Letters*. 2019; 18: 1351–1355.
- [67] Rodríguez-Trujillo A, Martí C, Angeles MA, Sierra A, Esteve R, Saco A, *et al.* Value of HPV 16/18 genotyping and p16/Ki-67 dual staining to predict progression to HSIL/CIN2+ in negative cytologies from a colposcopy referral population. *American Journal of Clinical Pathology*. 2018; 150: 432–440.
- [68] Huo X, Sun H, Cao D, Yang J, Peng P, Kong L, *et al.* Evaluation of cervical high-grade squamous intraepithelial lesions-correlated markers as triage strategy for colposcopy after co-testing. *OncoTargets and Therapy*. 2021; 14: 2075–2084.
- [69] Bowden SJ, Ellis LB, Kalliala I, Paraskeva M, Tighe J, Kechagias KS, *et al.* Protocol for a systematic review and meta-analysis of the diagnostic test accuracy of host and HPV DNA methylation in cervical cancer screening and management. *BMJ Open*. 2023; 13: e071534.
- [70] Nayar R, Wilbur DC. The Bethesda System for reporting cervical cytology: a historical perspective. *Acta Cytologica*. 2017; 61: 359–372.
- [71] Peeters E, Wentzensen N, Bergeron C, Arbyn M. Meta-analysis of the accuracy of p16 or p16/Ki-67 immunocytochemistry versus HPV testing for the detection of CIN2+/CIN3+ in triage of women with minor abnormal cytology. *Cancer Cytopathology*. 2019; 127: 169–180.
- [72] Qayoom S, Bharti A, Jaiswal R, Agarwal P, Singh R, Agarwal S, *et al.* Can dual staining with p16 and Ki67 be biomarkers of epithelial dysplasia in oral lesions? *Journal of Cancer Research and Therapeutics*. 2022; 18: 1003–1008.
- [73] Hosseini MS, Talayeh M, Afshar Moghaddam N, Arab M, Farzaneh F, Ashrafganjoei T. Comparison of Ki67 index and p16 expression in different grades of cervical squamous intraepithelial lesions. *Caspian Journal of Internal Medicine*. 2023; 14: 69–75.
- [74] Prevodnik VK, Marinsek ZP, Zalar J, Rozina H, Kotnik N, Jerman T, *et al.* Evaluation of the training program for p16/Ki-67 dual immunocytochemical staining interpretation for laboratory staff without experience in cervical cytology and immunocytochemistry. *Radiology and Oncology*. 2020; 54: 201–208.
- [75] Wentzensen N, Fetterman B, Tokugawa D, Schiffman M, Castle PE, Wood SN, *et al.* Interobserver reproducibility and accuracy of p16/Ki-67 dual-stain cytology in cervical cancer screening. *Cancer Cytopathology*. 2014; 122: 914–920.
- [76] Øvestad IT, Dalen I, Andersland MS, Vintermyr OK, Moltu P, Berland JM, *et al.* Triaging HPV-positive cervical samples with p16 and Ki-67 dual stained cytology within an organized screening program—a prospective observational study from western Norway. *International Journal of Molecular Sciences*. 2023; 24: 7158.
- [77] Pimple SA, Mishra GA, Deodhar KK. Evidence based appropriate triage strategies for implementing high risk HPV as primary technology in cervical cancer screening. *Minerva Ginecologica*. 2020; 72: 96–105.
- [78] Tantitamit T, Khemapech NP, Havanond P, Termrungruanglert W. Cost-effectiveness of primary HPV screening strategies and triage with cytology or dual stain for cervical cancer. *Cancer Control*. 2020; 27: 1073274820922540.
- [79] Li T, Chen S, Li X, Wu Z, Zhao Y, Cui J, *et al.* The features of high-risk human papillomavirus infection in different female genital sites and impacts on HPV-based cervical cancer screening. *Journal of Virology*. 2023; 20: 116.
- [80] Kundrod KA, Jeronimo J, Vetter B, Maza M, Murenzi G, Phoolcharoen N, *et al.* Toward 70% cervical cancer screening coverage: technical challenges and opportunities to increase access to human papillomavirus (HPV) testing. *PLOS Glob Public Health*. 2023; 3: e0001982.
- [81] Yu L, Chen X, Liu X, Fei L, Ma H, Tian T, *et al.* Significance of triple detection of p16/ki-67 dual-staining, liquid-based cytology and HR HPV testing in screening of cervical cancer: a retrospective study. *Frontiers in Oncology*. 2022; 12: 915418.
- [82] Sengupta M, Das D, Basu K, Tirkey M, Datta C, Chatterjee U. Role of p16/Ki-67 dual immunostaining in detection of cervical cancer precursors. *Journal of Cytology*. 2018; 35: 153–158.

- [83] Han C, Huang W, Ye M, Zou R, Lan J, Chen J, *et al.* HPV prevalence and genotype distribution in 2,306 patients with cervical squamous cell carcinoma in central and eastern China. *Frontiers in Public Health*. 2023; 11: 1225652.
- [84] Egawa N. Papillomaviruses and cancer: commonalities and differences in HPV carcinogenesis at different sites of the body. *International Journal of Clinical Oncology*. 2023; 28: 956–964.

How to cite this article: Ana Acosta Bedon, Dayanara Delgado-López, Cristina Ochoa-Avilés, Roque Rivas-Párraga, Bernardo Vega Crespo, Veronique Verhoeven, *et al.* p16/Ki-67 dual staining as a predictive value for cervical cancer compared to other conventional triage tools: a descriptive literature review. *European Journal of Gynaecological Oncology*. 2024; 45(4): 1-15. doi: 10.22514/ejgo.2024.062.